Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Eiger Biopharmaceuticals

10/03/2022 22:39

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a
quarterly
adjusted loss of 64 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 64 cents per share.
    * Revenue was $3.36 million​;  analysts expected $3.34
million. 
    * Eiger BioPharmaceuticals Inc's reported EPS for the
quarter was
a loss of 64 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Eiger BioPharmaceuticals Inc shares had fallen by 12.1%
this
quarter.
    * The company reported a quarterly loss of $21.77 million.
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $25.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated March 10 at 10:39 p.m.  ​All
figures in US dollars unless otherwise stated